12:00 AM
 | 
Jun 02, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALX-0171: Phase I data

An open-label, German Phase I trial in 24 adults with hyper-reactive airways showed that single ascending-doses of 2-200 mg ALX-0171 and once-daily 140 and 200 mg inhaled ALX-0171...

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >